<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981929</url>
  </required_header>
  <id_info>
    <org_study_id>AKF-375</org_study_id>
    <nct_id>NCT00981929</nct_id>
  </id_info>
  <brief_title>Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes</brief_title>
  <official_title>Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Cytochrome P450 enzymes are responsible for the metabolism of a wide range of drugs and
      other xenobiotics. Genetic variants of the encoding P450 genes have shown to influence the
      rate of metabolism of many clinically used drugs.

      The drugs tramadol, omeprazole, losartan, quinidine and caffeine reflect the activity of
      CYP2D6 (tramadol), CYP2C19 (omeprazole), CYP2C9 (losartan), CYP1A2 (caffeine) and CYP3A4/5
      (quinidine).

      The aim of the study is to investigate if the cocktail of tramadol, omeprazole, losartan and
      caffeine can be used to simultaneously determine the activity of CYP2D6, CYP2C19, CYP2C9 and
      CYP1A2. Furthermore, will the natural occurring 4-beta-hydroxy-cholesterol in the blood be
      measured as a metric for CYP3A4/5.

      The study is divided in two. First part will include 12 healthy volunteers and consists of
      three arms separated by at least one week. In the first arm 50 mg of tramadol will be
      ingested and urine will be collected for 8 hours. In the second arm 20 mg omeprazole, 25 mg
      losartan and 200 mg caffeine will be ingested followed by 8 hours urine collection and a
      blood sample 4 hours after administration of the drugs. In the last arm 50 mg of tramadol, 20
      mg omeprazole, 25 mg losartan and 200 mg caffeine will be ingested followed by 8 hours urine
      collection and a blood sample 4 hours after administration of the drugs.

      Metabolic ratios will be calculated based on urine and plasma concentrations of the drugs and
      the relevant metabolites. Relevant genetic variants of the cytochrome P450 encoding genes
      will be determined.

      If the metabolic ratios of the drugs are not significantly different between the arms, Second
      part of the study will be conducted.

      This part is identical with the last arm and will include a maximum of 400 healthy
      volunteers: 50 mg of tramadol, 20 mg omeprazole, 25 mg losartan and 200 mg caffeine will be
      ingested followed by 8 hours urine collection and a blood sample 4 hours after administration
      of the drugs.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unexpected non-serious adverse events
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic ratios</measure>
    <time_frame>January 2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genetic variants</measure>
    <time_frame>January 2011</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">412</enrollment>
  <condition>Cytochrome P450 Phenotype and Genotype Metrics</condition>
  <arm_group>
    <arm_group_label>Tramadol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CYP2D6 metric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omeprazole, losartan, caffeine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CYP2C19, CYP2C9 and CYP1A2 metrics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol, omeprazole, losartan and caffeine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CYP2D6, CYP2C19, CYP2C9 and CYP1A2 metrics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>50 mg single oral dose</description>
    <arm_group_label>Tramadol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole, losartan, caffeine</intervention_name>
    <description>20 mg omeprazole 25 mg losartan 200 mg caffeine</description>
    <arm_group_label>Omeprazole, losartan, caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol, omeprazole, losartan, caffeine</intervention_name>
    <description>50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine</description>
    <arm_group_label>Tramadol, omeprazole, losartan and caffeine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers,

          -  Written consent, AND

          -  Age 18-65 years old.

        Exclusion Criteria:

          -  Daily medication,

          -  Alcohol abuse,

          -  Pregnancy, OR

          -  Breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Southern Denmark, Clinical Pharmacology</name>
      <address>
        <city>Odense</city>
        <state>Fyn</state>
        <zip>D-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <last_update_submitted>June 24, 2010</last_update_submitted>
  <last_update_submitted_qc>June 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kim Brosen / Professor</name_title>
    <organization>University of Southern Denmark</organization>
  </responsible_party>
  <keyword>CYP2D6</keyword>
  <keyword>CYP2C9</keyword>
  <keyword>CYP2C19</keyword>
  <keyword>CYP1A2</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

